Cargando…
Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia
Despite the rapid development of medicine, even nowadays, acute lymphoblastic leukemia (ALL) is still a problem for pediatric clinicians. Modern medicine has reached a limit of curability even though the recovery rate exceeds 90%. Relapse occurs in around 20% of treated patients and, regrettably, 10...
Autores principales: | Jędraszek, Krzysztof, Malczewska, Marta, Parysek-Wójcik, Karolina, Lejman, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950780/ https://www.ncbi.nlm.nih.gov/pubmed/35328487 http://dx.doi.org/10.3390/ijms23063067 |
Ejemplares similares
-
Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia
por: Malczewska, Marta, et al.
Publicado: (2022) -
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
por: Lato, Marta Weronika, et al.
Publicado: (2021) -
The Importance of Selected Dysregulated microRNAs in Diagnosis and Prognosis of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
por: Ziętara, Karolina Joanna, et al.
Publicado: (2023) -
Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms
por: Lejman, Monika, et al.
Publicado: (2021) -
The Landscape of Secondary Genetic Rearrangements in Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia with t(12;21)
por: Kaczmarska, Agnieszka, et al.
Publicado: (2023)